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Amphotericin B (AmB) induces oxidative and nitrosative stresses, characterized by production of reactive oxygen and nitrogen
species, in fungi. Yet, how these toxic species contribute to AmB-induced fungal cell death is unclear. We investigated the role
of superoxide and nitric oxide radicals in AmB’s fungicidal activity in Saccharomyces cerevisiae, using a digital microﬂuidic
platform, which enabled monitoring individual cells at a spatiotemporal resolution, and plating assays. The nitric oxide synthase
inhibitor L-NAME was used to interfere with nitric oxide radical production. L-NAME increased and accelerated AmB-induced
accumulation of superoxide radicals, membrane permeabilization, and loss of proliferative capacity in S. cerevisiae. In contrast,
the nitric oxide donor S-nitrosoglutathione inhibited AmB’s action. Hence, superoxide radicals were important for AmB’s
fungicidal action, whereas nitric oxide radicals mediated tolerance towards AmB. Finally, also the human pathogens Candida
albicans and Candida glabrata were more susceptible to AmB in the presence of L-NAME, pointing to the potential of AmB-L-
NAME combination therapy to treat fungal infections.
1. Introduction
Pathogenic fungi, including Candida albicans and Candida
glabrata, encounter diverse environmental stresses when
colonizing human tissues. During the infection process,
they are exposed to potent reactive oxygen and nitrogen
species (ROS and RNS, resp.), including nitric oxide radical
(NO•), peroxynitrite (ONOO−), superoxide anion radical
(O2
−•), and hydroxyl radical (•OH), generated by the respira-
tory burst of phagocytic cells [1–3]. ROS and RNS cause
damage to DNA, proteins, and lipids and are toxic to most
fungi [4, 5]. In contrast to most nonpathogenic fungi, fungal
pathogens such as several Candida species have developed
responses to neutralize these toxic radicals and repair the
potential molecular damage [6]. In this respect, various pro-
teins that protect the fungus from oxidative and nitrosative
stresses have been identiﬁed and include signalling proteins,
transcription factors, and a variety of other enzymes such
as catalases, superoxide dismutases, peroxidases, and nitric
oxide dioxygenase [1, 7]. Hence, antifungals (or combina-
tions thereof) inducing an excess ROS and/or RNS in a path-
ogenic fungus that cannot be neutralized by its endogenous
protection mechanisms are of great interest [8].
Many antifungal agents are reported to induce oxidative
(excess ROS) stress in pathogenic fungi. These agents
include small molecules, such as miconazole [9, 10], ﬂucona-
zole [11, 12], amphotericin B (AmB) [12–16], and caspofun-
gin [17], but also antimicrobial peptides, such as protonectin
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[18], baicalin [19], and various plant defensins [20–23]. To
date, the induction of nitrosative (excess RNS) stress in
fungal species has only been demonstrated for AmB in the
pathogenic fungus Cryptococcus gattii [24] and for the plant
defensins NaD1 and PvD1 in C. albicans [23, 25]. AmB
belongs to the polyene class of antifungals and induces fungal
cell death through apoptotic and nonapoptotic pathways
[26–29]. Hence, based on the above reports, it seems that
AmB can induce both excess ROS and RNS in pathogenic
fungi. How the production of these diﬀerent types of radicals
would contribute to AmB’s fungicidal action is hitherto not
known. Moreover, increased insight in these AmB-induced
events may lead to more eﬃcient AmB-based therapies, as
exempliﬁed in the current study.
In this study, we further investigated the potential of
AmB to induce ROS and RNS and looked at the interplay
between these toxic radicals and their accumulation kinetics,
thereby linking these events to AmB’s killing capacity. To
investigate the kinetics of the AmB-induced ROS and RNS,
we used a digital microﬂuidic platform (DMF) in which sin-
gle cells were captured and monitored over time using time
lapse ﬂuorescence microscopy. This DMF platform has been
previously optimized for seeding of Saccharomyces cerevisiae
cells and subsequently for assessing the rate by which AmB-
induced membrane permeabilization events occurred at the
single cell level [30]. S. cerevisiae has been widely used to
investigate the mechanisms of action of antifungal agents,
including that of AmB [14, 31–35]. Hence, also in this study,
we used S. cerevisiae as a model organism to better under-
stand the mode of action of AmB and translated the most
prominent ﬁndings to the fungal pathogens C. albicans and
C. glabrata.
2. Methods
2.1. Strains and Chemical Reagents. Saccharomyces cerevisiae
strain BY4741, Candida albicans strain SC5314, and Candida
glabrata strain BG2 were used in the cytotoxicity assays. All
culture media were purchased from LabM Ltd. (Lancashire,
England), unless stated otherwise. Media used were YPD
(1% yeast extract; 2% peptone; and 2% glucose), 1/5 YPD
(YPD diluted in distilled water), and RPMI-1640 (Roswell
Park Memorial Institute-1640 medium; pH7) with L-
glutamine and without sodium bicarbonate (purchased from
Sigma-Aldrich, St. Louis, MO, USA), buﬀered with MOPS
(Sigma-Aldrich, St. Louis, MO, USA).
Amphotericin B (AmB), Nω-Nitro-L-arginine methyl
ester hydrochloride (L-NAME), S-nitrosoglutathione, propi-
dium iodide (PI), and dihydroethidium (DHE) were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
4-Amino-5-methylamino-2′,7′-diﬂuoroﬂuorescein diacetate
(DAF-FM DA) was supplied by Life Technologies (Carlsbad,
CA, USA). Peroxide was purchased from VWR chemicals
(Radnor, PA, USA).
Fluorinert FC-40 was purchased from 3M (St. Paul,
MN, USA), and chemicals for photolithopgraphy were
supplied by Rohm and Haas (Marlborough, MN, USA).
Fluoroalkylsilane Dynasylan® F 8263 was supplied by Evonik
(Essen, Germany). AZ1505 photoresist and Teﬂon-AF® were
obtained from Microchemicals GmbH (Ulm, Germany)
and Dupont (Wilmington, DE, USA), respectively. Parylene
C dimer and Silane A174 were purchased from Plasma
Parylene Coating Services (Rosenheim, Germany).
2.2. Cell Culture Conditions. S. cerevisiae, C. albicans, or C.
glabrata, grown overnight in YPD at 30°C and 250 rpm,
were diluted to an optical density (OD) of 0.15 measured
at λ = 600nm in a ﬂask containing 50mL of fresh YPD and
further cultured for 5 h at 30°C and 250 rpm (S. cerevisiae)
or 37°C and 200 rpm (Candida spp.), to obtain exponentially
growing cells. Cells were then pelleted by centrifugation
(3min, 4000 rpm), washed and resuspended in 1/5 YPD for
S. cerevisiae or RPMI-1640 medium for C. albicans and C.
glabrata to an OD of 3 for further use in the experiments.
2.3. Cytotoxicity Assays in Bulk. Exponentially growing cells
were supplemented with PI, DHE, or DAF-FM DA to a ﬁnal
concentration of 3μM, 17μM, and 5μM, respectively, and
subsequently treated either with DMSO or water (controls),
a range of AmB dosages (0.625μM–10μM, dissolved in
DMSO), 200mM L-NAME (dissolved in water), or a combi-
nation of the above, with a ﬁnal DMSO concentration of 1%
(v/v%). After mixing, the cell suspensions were transferred to
Eppendorf tubes, covered with a layer of silicon oil, placed on
a horizontal shaker at 5 rpm, and incubated in the dark for
3 h at room temperature to be compliant with the DMF
setup. In case of C. albicans and C. glabrata, however, the
assays were performed at 37°C to be clinically relevant. A
plating assay was carried out at the start of the treatment to
account for the number of cells at this point. After 3 h, cells
were pelleted (3min, 4000 rpm), washed and resuspended
in phosphate buﬀered saline (PBS), and subsequently plated
or subjected to ﬂow cytometry on a BD Inﬂux™ cell sorter.
In the plating assay, a 10-fold dilution series of the cell sus-
pensions was prepared in PBS and appropriate cell suspen-
sions were spread in YPD agar plates, after which the plates
were allowed to dry for 10min and incubated for 48h at
30°C to visualize the number of colony forming units (CFUs).
For ﬂow cytometry, cells were monitored for ﬂuorescence
at 540/608 nm (FL3 610_20), 485/515 nm (FL1 580_30),
or 495/515 nm (FL2 530_40) for detection of membrane
permeabilization with PI, detection of superoxide radical
accumulation with DHE, or detection of nitric oxide radical
accumulation with DAF-FM DA, respectively.
2.4. Cell Cycle Analysis. Aliquots of cells were collected at the
indicated time points and cells were pelleted, washed, and
ﬁxed with ethanol (70% v/v) for at least 30min at 4°C. Cells
were then resuspended in sodium citrate buﬀer (50mM
sodium citrate, pH7.5), sonicated and treated with RNAse
for 1 h at 50°C, followed by subsequent incubation with
20μg/ml proteinase K for 1 hour at 50°C. Cell DNA was then
stained overnight with SYBR Green 10,000 x (Molecular
Probes/Invitrogen, Carlsbad, CA), diluted 10-fold in Tris-
EDTA (pH8.0), and incubated overnight at 4°C. Before ﬂow
cytometry analysis, samples were diluted 1 : 4 in sodium cit-
rate buﬀer. The SYBR signals were measured using a BD LSR
II™ (Becton Dickinson, NJ, USA) with a 488nm excitation
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laser. Signals from 30,000 cells/sample were captured in FITC
channel (530 nm± 30 nm), at a ﬂow rate of about 1000 cells/s.
The percentage of cells in each phase of the cell cycle was
determined oﬄine with ModFit LT software (Verity Software
House, Topsham, ME).
2.5. Checkerboard Antifungal Assays. AmB (dissolved in
DMSO), L-NAME (dissolved in water), and S-
nitrosoglutathione (dissolved in water) were 2-fold serially
diluted across the columns and rows of a 96-well microtiter
plate. Subsequently, AmB dilutions were further diluted 10-
fold in 1/5 YPD. Next, 20μl volumes of these dilutions were
transferred to a microtiter plate, allowing the analysis of
unique combinations of two compounds. Exponentially
growing S. cerevisiae cells were diluted to an OD of 0.10,
measured at λ = 600nm, in 1/5 YPD, and subsequently,
80μl was added to the microtiter plate, resulting in a ﬁnal
DMSO concentration of 1% (v/v %). In parallel, the number
of colony forming units (CFU) of this exponential culture
was determined by plating assay. After 24 h of incubation at
30°C, the OD of the checkerboard plate was measured at
λ = 600nm, to examine the growth of S. cerevisiae cells.
Subsequently, a plating assay was performed of speciﬁc wells
of the checkerboard assay to assess cell viability of speciﬁc
AmB-L-NAME combinations. Based on preliminary data
of this experiment, we have performed power calculations
(α = 0 05; b = 0 8) for an AmB concentration of 0.313μM,
which is the tested value closest to the IC50 (0.282μM
AmB for S. cerevisiae). These calculations indicated that we
needed 2 biological replicates to assure a power of b = 0 8.
Recalculations of the power calculations, based on data of
the 2 biologically independent experiments, conﬁrmed the
previously executed power calculations.
2.6. Fabrication of Digital Microﬂuidic Plates. Digital micro-
ﬂuidic plates were fabricated as described previously [30].
The assembly consists of an actuation plate and a grounding
plate, as presented in Supplemental Information S3 Figure
available online at https://doi.org/10.1155/2017/4064628.
For fabricating the actuation plate (S3 Figure A), cleaned
glass wafers (1.1mm) were sputter coated with chromium
(100nm) and patterned using standard photolithographic
processes. After cleaning the plates with acetone and iso-
propyl alcohol twice, the surface was plasma activated
(O2 plasma, 150 mtorr, 100W) and the plates were primed
with Silane A174 to promote adhesion of the parylene C
layer (3μm) that was subsequently coated using chemical
vapour deposition. Next, a thin layer of Teﬂon-AF
(200 nm, using 3% w/w in Fluorinert FC-40) was spin-
coated (1200 rpm) on top of the parylene C layer and baked
for 5min at 110°C and 5min at 200°C. Crenelated actuation
electrodes with dimensions of 2.8mm× 2.8mm were selec-
tively actuated to manipulate individual droplets of 2.7μL,
using customized software.
For fabrication of the grounding plate (Supplemental
Information S3A Figure) of the DMF device, cleaned glass
wafers (1mm) were coated with an aluminium layer (40 nm)
using thermal evaporation, leaving two 2.5× 2.5mm visu-
alization windows. Fluoroalkylsilane Dynasylan F 8263
was coated on the aluminium to improve adhesion of the
subsequent spin-coated Teﬂon-AF layer (3μm). Microwells
were patterned in the Teﬂon-AF layer following a hard con-
tact masking procedure, developed by depositing parylene C
(1μm) and aluminium (60–80 nm) layers. A thin layer of
AZ1505 photoresist was spin-coated on the aluminium layer,
and the aluminium was patterned and etched using standard
photolithography processes. The pattern was then trans-
ferred from the aluminum to the Teﬂon-AF using O2 plasma
(150 mtorr, 100W) for 10min. Finally, using a dry lift-oﬀ
method, the aluminium-parylene C mask was peeled oﬀ
using a pair of forceps, revealing two microwell arrays
(1.9mm× 1.9mm) on a single grounding plate, consisting
of 22,000 microwells each, arranged in a hexagonal pattern
with a pitch distance of 14μm [36]. The dimensions of the
microwells were measured to be approximately 5.5μm in
width and 3μm in depth.
2.7. Cytotoxicity Assays on DMF Platform. A schematic over-
view of the cytotoxicity assays on the DMF platform is given
in Supplemental Information S3B Figure. Exponentially
growing cells were supplemented with PI or DHE to a ﬁnal
concentration of 3μM and 17μM, respectively, and subse-
quently treated either with DMSO or water (controls), a
range of AmB dosages (5μM and 10μM, dissolved in
DMSO), 200mM L-NAME (dissolved in water), or a combi-
nation of the above, with a ﬁnal DMSO concentration of 1%
(v/v %). After 5min, two droplets, one containing the mixed
cell suspension and one containing the corresponding com-
position without cells, were placed on two separate electrodes
of the actuation plate. The actuation and grounding plate
were assembled, thereby aligning the microwell array with
the cell droplet and sandwiching it between the plates. To
prevent sticking and evaporation of the droplets, 80μL of
silicon oil was added between the plates by pipetting. The
assembled plates were placed in the DMF chip holder, and
the device was ﬂipped upside down and incubated for
10min to allow sedimentation of the cells. This step was
followed by automated shuttling of the cell droplet over the
microwell array for 15 times, that is, 15 seeding cycles, using
software-assisted electrowetting-on-dielectric (EWOD) actu-
ation. After seeding, the cell droplet was actuated away from
the array and a droplet without cells was transferred to the
array. The cell responses, that is, membrane permeabilization
detected by PI or superoxide radical accumulation detected
by DHE, were monitored at room temperature for 3 h in
15min intervals using an inverted ﬂuorescence microscope
(IX-71, Olympus, Tokyo, Japan) equipped with a CCD
camera. The whole array was scanned in 9 overlapping
frames in approximately 15 seconds, in which a single frame
covered approximately 4100 wells, using a 20x lens magni-
ﬁcation. Both ﬂuorescence and bright ﬁeld images were
collected using the same excitation/emission wavelengths
as described above.
2.8. Calculation of Fluorescence Intensity per Cell. The DMF
array was imaged for 3 h in 15min intervals (i.e., 12 time
points), and images were processed in ImageJ (v1.47, NIH,
MD) for background correction using rolling ball algorithm
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with a radius of 50 pixels. Salt-and-pepper noise was
removed using the despeckle option in ImageJ. Next, the
images were loaded in MATLAB (The Mathworks, Natick,
MA), and a custom MATLAB code was executed. The single
image captured at 180min was processed by MATLAB to
identify the single ﬂuorescent cells in contrast with the
background. The MATLAB code detected the area of a single
cell, and a unique numerical digit was allotted to each cell.
Within the detected area of a single cell, the maximum pixel
value was registered together with its respective coordinate
in a vector array. Next, the MATLAB code was executed
on all the images captured between 15min and 165min.
The ﬂuorescence intensity of each individual cell in diﬀer-
ent time frames was monitored by detecting the pixel
values for the registered coordinates. The ﬁnal output
was tabular data with pixel intensities of single cells identiﬁed
with unique numerical digits, as detected in 12 consecutive
time points.
2.9. Data Analysis. Flow cytometric data were normalized to
the control data, and DMF data were normalized to the ﬁrst
data point, that is, 15min. For plating assays, the number of
CFUs per mL was displayed in Log scale. Data were analysed
with GraphPad Prism 6 SPPS (GraphPad Software, Inc., CA,
USA). Two-way ANOVA followed by Dunnett multiple
comparison test was performed to analyse statistically signif-
icant diﬀerences in the number of PI-, DHE-, and DAF-FM
DA-positive cells and cells able to proliferate between control
and diﬀerent AmB treatments in S. cerevisiae, C. albicans,
and C. glabrata. Pearson’s product-moment correlation was
performed to analyse the relation between the results
obtained in the bulk and the DMF experiments. Survival
analyses (Kaplan-Meier) using the Log-rank test were per-
formed on DMF data to compare survival curves and analyse
whether treatment signiﬁcantly aﬀects survival. Two-way
ANOVA and subsequent Tukey or Dunnett multiple com-
parison tests were performed to analyse diﬀerences between
bulk results for treatment with AmB in the presence or
absence of L-NAME for each AmB concentration or to
analyse diﬀerences in bulk results between the ﬁrst data
point and other data points within the same treatment,
respectively. Two-way ANOVA followed by Tukey multiple
comparison test was performed to analyse statistically signif-
icant diﬀerences between diﬀerent treatments in the cell cycle
analyses. Two-way ANOVA followed by Tukey multiple
comparison test was performed to analyse statistical diﬀer-
ences between the OD measurements for treatment with dif-
ferent concentrations of AmB in the absence or presence
of 200mM L-NAME or 2mM S-nitrosoglutathione. In all
cases, P < 0 05 was considered statistically signiﬁcant. When
multiple comparisons were performed, multiplicity-adjusted
P values for each comparison are presented, taking into
account the total number of groups in the ANOVA and the
data in all groups.
3. Results
3.1. Amphotericin B Induced Nitric Oxide and Superoxide
Radical Accumulation in Saccharomyces cerevisiae. First, we
assessed whether AmB induces accumulation of superoxide
and nitric oxide radicals in S. cerevisiae. To this end, yeast
cultures were treated with AmB for 3 h at room temperature
to be compliant with the DMF setup and subjected to ﬂow
cytometry to analyse the number of cells with increased
superoxide and nitric oxide radical levels using DHE and
DAF-FM DA dyes, respectively. The ﬂuorescent probe
DHE is typically used for detecting O2
−• due to its relative
speciﬁcity for this ROS, with minimal oxidation induced by
H2O2 or hypochlorous acid [37, 38]. Furthermore, in contrast
to other intracellular dyes, there is little capacity for the for-
mation of superoxide by DHE due to redox cycling [38].
However, nonspeciﬁc oxidation of DHE from other nonsu-
peroxide sources, such as cytochrome c [38], was not elimi-
nated in this study. The number of cells with compromised
plasma membranes was analysed using PI. As PI only enters
cells with compromised plasma membrane, it was used as a
marker to identify nonapoptotic cell death [39]. To quantify
the fungicidal activity of AmB, the treated cultures were sub-
jected to plating assays, thereby assessing the number of cells
that was able to proliferate after AmB treatment.
The number of cells that accumulated superoxide
(Figure 1(a)) and nitric oxide radicals (Figure 1(b)), as well
as the number of cells with permeabilized membranes
(Figure 1(c)), was signiﬁcantly increased by AmB treatment
in a dose-dependent manner (P < 0 05), while the prolifer-
ative capacity of the cells was decreased, yet, not statisti-
cally signiﬁcant (Figure 1(d)). This dose dependency was
diﬀerent for the tested responses: a maximum number of
cells producing nitric oxide radicals in AmB-treated yeast
cultures were found at AmB concentrations as low as
2.5μM (P < 0 0001) (Figure 1(b)), whereas the highest num-
ber of cells with increased superoxide radical accumulation
and compromised membranes was observed at 10μM AmB
(P < 0 0001) (Figures 1(a) and 1(c), resp.). Hence, it seemed
that the production of nitric oxide radicals could be induced
at AmB doses that did not trigger the accumulation of super-
oxide radicals or membrane permeabilization, while this
resulted in a reduced proliferative capacity of cells.
3.2. Inhibition of Nitric Oxide Radical Production Resulted in
Increased Superoxide Radical Accumulation and Loss of
Proliferative Capacity by Amphotericin B. As it was previ-
ously shown that superoxide radicals react with nitric oxide
radicals, resulting in strongly oxidizing RNS causing damage
to proteins and nucleic acids [40–42], we investigated
whether the AmB-induced superoxide radical levels could
be increased by blocking the production of nitric oxide radi-
cals. To this end, L-NAME was used. L-NAME inhibits nitric
oxide synthases in mammalian cells and thus prevents the
generation of nitric oxide radicals [43]. Although in yeast,
only nitric oxide synthase-like enzymes are identiﬁed to date,
L-NAME was shown to reduce the levels of nitric oxide rad-
icals in yeast [44–46]. Reduction of the levels of nitric oxide
radicals by L-NAME in S. cerevisiaewas microscopically con-
ﬁrmed (data not shown).
In the presence of L-NAME, the number of cells with
AmB-induced accumulation of superoxide radicals signiﬁ-
cantly increased as compared to that after AmB treatment
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alone, in the case of 2.5μM or 10μM AmB (Figure 2(a);
P = 0 05 and P < 0 0001, resp.). Moreover, treatment of
yeast with 1.25μM or 2.5μM AmB supplemented with L-
NAME signiﬁcantly reduced the number of cells that were
able to proliferate, as compared to treatment with AmB alone
(Figure 2(c); P = 0 01 and P < 0 0001, resp.). In contrast, only
10μM AmB with L-NAME increased the number of cells
with a compromised membrane in a signiﬁcant manner
(P = 0 02), as compared to that after treatment with AmB
alone (Figure 2(b)), suggesting that the combination of low
concentrations of AmB with 200mM L-NAME did not aﬀect
membrane permeabilization by AmB. In addition, inhibition
of nitric oxide radical production resulted in an increased
number of cells that accumulated superoxide radicals and
was characterized by membrane permeabilization and inabil-
ity to proliferate. These ﬁndings point towards a potential
role of nitric oxide radical production in mediating tolerance
towards AmB in yeast. Moreover, we have performed cyto-
toxicity assays with peroxide in the presence and absence of
200mM L-NAME and found that L-NAME can only
increase the killing activity of AmB but not that of peroxide,
implying an AmB-speciﬁc eﬀect of L-NAME (Supplemental
Information S4 Figure).
3.3. Inhibition of Nitric Oxide Radical Production Resulted in
Faster and Increased Superoxide Radical Accumulation and
Faster Membrane Permeabilization by Amphotericin B. To
gain more insights into the action of L-NAME on the
kinetics of AmB-induced superoxide radical accumulation,
time lapse experiments were performed on a DMF platform
(for a schematic representation of the experimental setup,
see Supplemental Information S3 Figure), as described in
our previous study [30]. To this end, yeast was treated with
either 0μM (control), 5μM, or 10μM AmB in the presence
0
0 0.625 1.25 2.5 5
⁎
⁎
⁎
⁎
⁎
⁎
⁎
⁎
10
20
40
60
80
100
AmB concentration (휇M)
D
H
E-
po
sit
iv
e c
el
ls 
(%
)
(a)
0 0.625 1.25 2.5 5 10
AmB concentration (휇M)
0
20
40
60
80
100
D
A
F-
FM
 D
A-
po
sit
iv
e c
el
ls 
(%
)
⁎
⁎
⁎
⁎
⁎
⁎
⁎
⁎
⁎
⁎
⁎
⁎
⁎
⁎
⁎
(b)
0 0.625 1.25 2.5 5 10
AmB concentration (휇M)
0
20
40
60
80
100
PI
-p
os
iti
ve
 ce
lls
 (%
)
⁎
⁎
⁎
⁎
⁎
⁎
⁎
(c)
0 0.625 1.25 2.5 5 10
AmB concentration (휇M)
0
2
4
6
8
Lo
g 
(C
FU
/m
L)
(d)
Figure 1: AmB induced accumulation of superoxide and nitric oxide radicals and membrane permeabilization in S. cerevisiae. Yeast cultures
were treated with diﬀerent concentrations of AmB for 3 h and subjected to ﬂow cytometry or plating assays. (a) Levels of superoxide radical
detected by dihydroethidium (DHE) ﬂuorescence and ﬂow cytometry. (b) Levels of nitric oxide radical detected by 4-amino-5-methylamino-
2′,7′-diﬂuoroﬂuorescein diacetate (DAF-FM DA) ﬂuorescence and ﬂow cytometry. (c) Membrane permeabilization events detected by
propidium iodide (PI) ﬂuorescence and ﬂow cytometry. (d) Number of CFU/mL in Log-scale, assessed by plating assays and CFU
counting. Means and standard errors of the means (SEM) of at least 3 independent biological experiments (n ≥ 3) are presented. Two-way
ANOVA followed by Dunnett multiple comparison test was performed to analyse statistically signiﬁcant diﬀerences in the number of PI-,
DHE-, and DAF-FM DA-positive cells and cells able to proliferate between control treatment and treatment with diﬀerent concentrations
of AmB. ∗∗∗ and ∗∗∗∗ represent P < 0 001 and P < 0 0001, respectively.
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or absence of 200mM L-NAME, as these concentrations
were shown to have the most profound eﬀect on membrane
permeabilization and accumulation of superoxide radicals
in the bulk experiments. During treatment, each cell was
monitored over time at room temperature for 3 h in 15min
intervals for DHE or PI ﬂuorescence. Validation of the
DMF platform to monitor DHE and PI ﬂuorescence at single
cell level was performed prior to the assays described above
(Supplemental Information S1 Figure).
We found an increased number of DHE- (Figure 3(a))
and PI- (Figure 3(b)) positive cells when yeast was treated
with AmB supplemented with 200mM L-NAME as
compared to treatment with AmB alone, starting from
30min to 45min incubation, respectively. This observa-
tion was in line with the bulk results after 3 h of incu-
bation at room temperature that were obtained by ﬂow
cytometry (Figure 2).
Survival analyses were performed to test the hypothesis
that diﬀerent treatments (i.e., AmB in the presence or
absence of L-NAME) aﬀect survival in a signiﬁcantly diﬀer-
ent manner, in which survival is deﬁned as the occurrence
of a speciﬁc event [47]. Here, we analysed whether the occur-
rence of superoxide radical accumulation and membrane
permeabilization upon treatment with AmB in the presence
and absence of L-NAME was signiﬁcantly diﬀerent. The sur-
vival curves for treatment with 10μM AmB in the presence
or absence of 200mM L-NAME were signiﬁcantly diﬀerent
in both DHE and PI experiments (P < 0 0001) (Figures 3(a)
and 3(b)), indicating that L-NAME signiﬁcantly aﬀected
the number of superoxide radical accumulating cells and
the number of membrane permeabilization events induced
by AmB over time. When cells were treated with 10μM
AmB in combination with 200mM L-NAME, a median sur-
vival of 45min was observed in the DHE experiments, that is,
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Figure 2: AmB-induced superoxide radical accumulation, membrane permeabilization, and loss of proliferative capacity can be increased by
blocking nitric oxide radical production using L-NAME. Exponential yeast cultures were treated with diﬀerent concentrations of AmB
in the presence or absence of 200mM L-NAME for 3 h. (a) Levels of superoxide radical detected by dihydroethidium (DHE)
ﬂuorescence and ﬂow cytometry. (b) Membrane permeabilization events detected by propidium iodide (PI) ﬂuorescence and ﬂow
cytometry. (c) Number of CFU/mL in Log-scale, assessed by plating assays and CFU counting. Means and standard errors of the means
(SEMs) of at least 3 independent biological experiments (n ≥ 3) are presented. Black bars represent treatment with AmB alone; white bars
represent treatment with AmB supplemented with 200mM L-NAME. Two-way ANOVA followed by Tukey multiple comparison test was
performed to analyse signiﬁcant diﬀerences between the two treatments. ∗ and ∗∗∗∗ represent P < 0 05 and P < 0 0001, respectively.
Multiplicity-adjusted P values are presented in the text.
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Figure 3: L-NAME increased and accelerated AmB-induced superoxide radical accumulation, membrane permeabilization, and intracellular
superoxide radical levels. (a-b) Accumulation of superoxide radicals (a) and membrane permeabilization (b) in S. cerevisiae cells treated either
with 0μM (black), 5 μM (orange), or 10μM (blue) AmB in the presence (dashed lines) or absence (solid lines) of 200mML-NAME during 3 h
in 15min intervals. Log-rank tests were performed to analyse signiﬁcant diﬀerences between AmB treatment and treatment of AmB in
combination with 200mM L-NAME for each AmB dose. Data of at least 3 independent biological experiments is presented (n ≥ 3). ∗ and
∗∗∗∗ represent P < 0 05 and P < 0 0001, respectively. (c-d) Intracellular DHE ﬂuorescence in S. cerevisiae cells treated with 10μM AmB
in the absence (c) or presence (d) of 200mM L-NAME. Single cells were monitored for their DHE ﬂuorescence during treatment
for 3 h in 15min intervals using ﬂuorescence microscopy and the DMF platform. The ﬂuorescence intensity of each cell is presented as
arbitrary units (AU), and each dot represents a single cell. Means and standard errors of the means (SEMs) of at least 3 independent
biological experiments (n ≥ 3), with at least 780 cells each, are presented. Two-way ANOVA followed by Tukey multiple comparison test
was performed to analyse signiﬁcant diﬀerences in DHE ﬂuorescence intensity. ∗ , ∗∗∗ , and ∗∗∗∗ represent P < 0 05, P < 0 001, and
P < 0 0001, respectively. (e) DHE ﬂuorescence intensity of individual cells over time. A selection of 35 cells was randomly chosen and is
representative for more than 3000 cells that were analysed in this study. Each plot represents the DHE ﬂuorescence intensity, measured
every 15min, of one representative cell over the whole duration of the experiment, that is, 180min.
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50% of the cells was DHE positive after 45min of treatment.
In contrast, when AmB was applied alone, 50% of DHE-
positive cells in the treated yeast culture was not reached after
180min (median survival> 180min), which implied that
AmB-induced superoxide radical accumulation occurred fas-
ter in cells treated in the presence of L-NAME. Additionally,
a hazard ratio (Log-rank) of 4.21 was found when comparing
the survival curve of cells treated with 10μM AmB supple-
mented with 200mM L-NAME to that of cells treated with
10μM AmB, indicating that the rate by which superoxide
radicals were formed is 4.21 times faster in the combination
treatment, compared to treatment with AmB alone. The
same was true for membrane permeabilization events
induced by AmB supplemented with L-NAME; upon treat-
ment with the latter, a median survival of 180min was
observed, as compared to >180min for treatment with
AmB alone, and when comparing both survival curves, a haz-
ard ratio of 1.56 was found. This suggested also that mem-
brane permeabilization occurred faster when cells were
subjected to AmB in the presence of L-NAME, as compared
to treatment with AmB alone.
We further conﬁrmed that the fast increase in superoxide
radical levels during AmB-L-NAME combination treatment
was linked to a block in the production of nitric oxide
radicals. As we were unable to monitor nitric oxide radicals
over time using the DMF platform due to an incompatibility
of the DAF-FM DA dye and the DMF setup, we opted to
further investigate the kinetics of nitric oxide radical produc-
tion by ﬂow cytometry. Indeed, upon AmB treatment, yeast
cells started to produce nitric oxide radicals from 30min
onwards (P < 0 0001), and a similar trend was observed to
that of superoxide radical accumulation during treatment
with AmB supplemented with L-NAME (Supplemental
Information S2 Figure).
To further elucidate the variation of superoxide radical
levels when cells were subjected to AmB treatment in the
presence of L-NAME, we analysed the ﬂuorescence intensity
of individual cells. To this end, single cells were monitored
over time in 15min intervals, and hence the ﬂuorescence
intensity of each cell, represented by one dot, was reanalysed
every 15min. We found that the DHE ﬂuorescence intensity
of cells during AmB treatment gradually increased over
time, and the highest ﬂuorescence intensity was measured
at 180min, the end point of this study (Figure 3(c)). Com-
pared to the DHE ﬂuorescence at 15min, the DHE ﬂuores-
cence intensity was signiﬁcantly diﬀerent from 135min
onwards. In contrast, the DHE ﬂuorescence intensity of cells
treated with 10μM AmB supplemented with 200mM L-
NAME showed two subpopulations, suggesting that superox-
ide radical accumulation took place in a biphasic manner; the
ﬁrst and highest superoxide radical accumulation peak was
observed at approximately 75min, followed by a rather slow
decrease and a second peak at approximately 150min
(Figure 3(d)). Here, the DHE ﬂuorescence intensity was
statistically signiﬁcant from 60min onwards (compared to
DHE ﬂuorescence at 15min). The kinetics of DHE ﬂuores-
cence of 35 individual cells, representative for more than
3000 analysed cells, showed diﬀerent subsets of cells in ROS
readouts over time. Some subsets showed an increase in
DHE ﬂuorescence, followed by a decrease in ﬂuorescence at
certain time points, while other subsets showed a gradual
increase in ﬂuorescence over time (Figure 3(e)). Hence, it
seemed that not only the number of cells accumulating
superoxide radicals increased when subjected to AmB treat-
ment in the presence of L-NAME, but also the intracellular
levels of superoxide radicals were altered in a time-
dependent manner, as compared to treatment of cells with
AmB alone.
Moreover, to further support the data of the single cell
analysis via the DMF platform, we performed additional
time lapse experiments in bulk via FACS and analysed the
subpopulations of DHE- and PI-positive cells of cultures
treated with 10μM AmB in the presence and absence of
200mM L-NAME for 30, 60, 90, and 180min. We found
an increased number of DHE- and PI-positive cells when
yeast was treated with 10μM AmB supplemented with
200mM L-NAME as compared to treatment with AmB
alone, starting from 30min to 90min incubation, respec-
tively (Supplemental Information S5 Figure). These bulk
data showed faster and increased ROS accumulation and fas-
ter membrane permeabilization by AmB when coincubated
with L-NAME and corroborated the data of the single cell
analysis via the DMF platform. Note that the number of
PI-positive cells induced by AmB in the presence of L-
NAME is higher when assessed in bulk as compared to the
DMF setup.
3.4. Inhibition of Nitric Oxide Radical Accumulation Resulted
in Faster Arrest of Proliferative Capacity of Saccharomyces
cerevisiae Cells by Amphotericin B. The results described
above indicate that AmB-induced superoxide radical accu-
mulation and membrane permeabilization were signiﬁcantly
altered upon the addition of L-NAME. This tempted us to
further investigate whether the proliferative capacity of cells
was aﬀected in a time-dependent manner, when comparing
both treatments. To this end, plating of S. cerevisiae cultures
subjected to both treatments was carried out every 15min,
and the number of cells that were able to proliferate (and
form CFU) was determined.
At all time points, the proliferative capacity of cells
treated with 10μM AmB and 200mM L-NAME was signiﬁ-
cantly reduced as compared to cells treated with 10μMAmB
alone (P < 0 0001) (Figure 4(c)). In addition, it seemed that
the proliferative capacity of cells subjected to AmB-L-
NAME treatment was reduced very fast, that is, within
15min (P < 0 0001), whereas the proliferative capacity of
cells upon treatment with AmB alone decreased in a signiﬁ-
cant manner from 45min onwards (P = 0 003). This sug-
gested that the fast decrease in proliferative capacity of cells
within 15min upon incubation with AmB and L-NAME
was independent of superoxide radical accumulation and
membrane permeabilization. Similar observations were
made in the survival analyses for superoxide radical accumu-
lation and membrane compromising events (Figures 3(a)
and 3(b)) and were supported by a second statistical analysis
(Two-way ANOVA followed by Dunnett multiple compari-
son test). Speciﬁcally, a signiﬁcant diﬀerence in the number
of cells accumulating superoxide radicals (Figure 4(a)) and
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showing membrane permeabilization (Figure 4(b)) was
found at earlier time points (i.e., 45min versus 105min for
superoxide radical accumulation and 60min versus 105min
for membrane permeabilization) when cells were treated
with AmB in the presence of L-NAME, as compared to cells
treated with AmB alone.
However, although approximately 99.5% of the treated
population was not able to proliferate from 15min onwards
(Figure 4(c)) when subjected to AmB-L-NAME treatment,
they were still able to accumulate superoxide radicals at
that point, which resulted in a superoxide radical boost
starting at 30min (Figure 4(a)). Hence, it seemed that
these cells were still metabolically active and possibly used
increased intracellular superoxide radical levels to enter a
programmed cell death pathway. In contrast, loss of prolifer-
ative capacity of cells treated with AmB alone (Figure 4(c))
might be explained by the gradual increase in the number
of membrane permeabilization events; a similar trend in both
curves was observed (Figure 4(b)).
To further conﬁrm the crucial role of nitric oxide in
modulating AmB’s fungicidal activity, we performed
checkerboard assays with AmB and the nitric oxide
donor, S-nitrosoglutathione. We found that 2mM S-
nitrosoglutathione reduced the activity of AmB (Figure 5).
Hence, nitric oxide plays an important role in modulating
AmB’s activity.
3.5. Amphotericin B Induced Cell Cycle Arrest in
Saccharomyces cerevisiae Independently of L-NAME.We fur-
ther analysed whether the increased loss of proliferative
capacity upon combined AmB and L-NAME treatment
within 15min of treatment can be attributed to cell cycle
arrest. To this end, we analysed the fraction of cells in the
G0/G1, S, and G2/M cell cycle phases at the beginning and
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Figure 4: L-NAME decreased the proliferative capacity of cells during AmB treatment, which seems independent of superoxide radical
accumulation. Exponential yeast cells were treated with 10 μM AmB in the presence (white bars) or absence (black bars) of 200mM L-
NAME for 3 h. Cells were analysed for their DHE and PI ﬂuorescence in the DMF setup (a and b) or subjected to bulk plating assays (c)
every 15min. Means and standard error of the means (SEMs) of at least 3 independent biological experiments (n ≥ 3) are presented. Two-
way ANOVA followed by Tukey multiple comparison test was performed to analyse signiﬁcant diﬀerences between the two treatments;
Two-way ANOVA followed by Dunnett multiple comparison test was performed to analyse signiﬁcant diﬀerences between the ﬁrst data
point (i.e., 0min (in (c)) or 15min (in (a) and (b))) and other data points within the same treatment (only the primary signiﬁcant
diﬀerence is presented to avoid overcrowding of the ﬁgure); ∗ , ∗∗ , and ∗∗∗∗ represent P < 0 05, P < 0 01, and P < 0 0001, respectively.
A dotted line is shown at 15min to point out the clear diﬀerences between the responses at this time point.
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after 7.5 and 15min of incubation with either AmB alone or
AmB supplemented with L-NAME.
AmB induced cell cycle arrest in the G2/M phase in
yeast at 15min of treatment, as compared to control cells
(P < 0 0001) (Figure 6). Interestingly, treatment with L-
NAME alone resulted in a decrease in the amount of cells
in the S phase at 7.5 and 15min (P = 0 03 and P = 0 0009,
resp.) and an increase in the amount of cells in the G2/M
phase at 15min (P = 0 03), compared to control-treated
cells. Yet, L-NAME alone did not increase the other cell
cycle phase distributions in a signiﬁcant manner at both
time points, compared to control-treated cells (P > 0 05 at
7.5min and 15min of treatment). Treatment with AmB-L-
NAME did not signiﬁcantly alter cell cycle phase distribu-
tions as compared to those in treatment with AmB alone,
suggesting that the observed increased loss of proliferative
capacity of yeast cells treated with the AmB-L-NAME combi-
nation, compared to AmB treatment alone, was not due to
increased cell cycle arrest.
3.6. Candida albicans and Candida glabrata Were More
Susceptible to Amphotericin B Treatment in the Presence of
Nitric Oxide Radical Production Inhibitors. To validate the
results obtained in yeast and in support of the clinical rel-
evance of AmB treatment in the presence of L-NAME, we
investigated the eﬀects of this treatment on the human
pathogen Candida albicans. We conﬁrmed that AmB
induced superoxide and nitric oxide radical accumulation
(P < 0 0001 at 10μM AmB), associated with loss of prolifer-
ative capacity, in C. albicans, in a similar dose-dependent
way as was observed for S. cerevisiae (Figure 7). These results
indicated that the range of AmB concentrations used for S.
cerevisiae was applicable for C. albicans as well. Further-
more, we assessed whether treatment at 37°C with AmB
in the presence of L-NAME also signiﬁcantly aﬀected the
number of cells that are able to proliferate as compared
to treatment with AmB alone. At 37°C, we found that
5μM AmB resulted in killing of the C. albicans culture
by 2 Log units (99.00%) and 10μM AmB by 4 Log units
(99.99%). These values are in line with the reported minimal
fungicidal concentration (MFC) of AmB (8.66μM) in a sim-
ilar experimental setup [48]. Coincubation of 200mM L-
NAME and 5μM AmB signiﬁcantly reduced the number of
CFUs as compared to treatment with AmB alone (P < 0 05)
(Figure 8(a)), indicating that L-NAME also enhanced
AmB’s fungicidal activity against C. albicans. Also, in case
of C. glabrata, we found that 10μM AmB resulted in killing
of C. glabrata by 4 Log units (99.99%). These values are in
line with the reported MFC of AmB against C. glabrata
(17μM) [49]. Also here, 200mM L-NAME signiﬁcantly
increased AmB’s fungicidal activity against C. glabrata
(Figure 8(b)). All these data point to the clinical potential of
combining AmB with L-NAME.
4. Discussion
The aim of this study was to investigate and understand
how AmB-induced oxidative and nitrosative stresses (char-
acterized by excess of superoxide radicals and nitric oxide
radicals, resp.) are linked to fungal cell death. To inhibit
the generation of nitric oxide radicals and nitrosative stress
in cells, we used the nitric oxide synthase inhibitor L-
NAME. From the bulk studies, we found that superoxide rad-
ical accumulation increased when nitric oxide production
was inhibited, thereby increasing AmB’s antifungal activity.
We then further assessed the kinetics of superoxide radical
accumulation, membrane permeabilization, and loss of pro-
liferative capacity using a DMF platform in which individual
S. cerevisiae cells were captured and monitored for their
responses over time during treatment. As seeding of C. albi-
cans was problematic due to the presence of hyphae, we ﬁrst
tested our hypotheses on S. cerevisiae and translated the most
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Figure 5: The nitric oxide donor, S-nitrosoglutathione, inhibited the killing activity of AmB. Yeast cells were treated with diﬀerent
concentrations of AmB, in the absence (black) or presence of 200mM L-NAME (blue) or 2mM S-nitrosoglutathione (orange). Means and
standard errors of the means (SEMs) of at least two independent biological experiments (n ≥ 2) are presented. The number of CFU/mL for
diﬀerent treatments (insert) was assessed by plating assays and CFU counting and is shown relative to the number of CFU/mL at the start
of the experiment. Two-way ANOVA followed by Tukey multiple comparison test was performed to analyse signiﬁcant diﬀerences
between the two treatments; ∗ and ∗∗∗∗ represent P < 0 05 and P < 0 0001, respectively.
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prominent ﬁndings to C. albicans and C. glabrata afterwards
using bulk assays. We showed that L-NAME increased and
accelerated the eﬀect of AmB on the accumulation of super-
oxide radicals, membrane permeabilization, and loss of pro-
liferative capacity in S. cerevisiae. Moreover, we showed
that the data obtained via time lapse experiments in bulk cor-
roborates the data of the single-cell analysis via the DMF
platform (Supplemental Information S5 Figure). We revealed
that superoxide radicals are important mediators for AmB-
induced fungal cell death. However, L-NAME could only
increase the killing potential of AmB, but not that of
peroxide. This implies an AmB-speciﬁc eﬀect of L-NAME
and might point to L-NAME’s eﬀects via an ergosterol-
dependent pathway. Indeed, ROS generation by AmB has
been described as a consequence of AmB’s spontaneous
insertion into ergosterol-containing membranes [50, 51]. In
contrast, nitric oxide radicals seemed to play a role in medi-
ating tolerance towards AmB, pointing to a beneﬁcial role
of nitric oxide radicals in the yeast response towards AmB.
We found that cellular responses are classiﬁed into two
groups based on the time point that they occur, that is, within
15min and from 30 to 45min onwards (Figure 9).
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Figure 6: Amphotericin B induced cell cycle arrest in the G2/M phase in yeast. Exponential yeast cultures were treated with either control (1%
DMSO; 10%mQ), 200mM L-NAME (dissolved in mQ), 10 μMAmB (dissolved in DMSO), or a combination of the above for 7.5min (a) and
15min (b). After treatment, cells were washed with PBS, ﬁxed in 70% EtOH, stained with PI, and subjected to ﬂow cytometry for cell cycle
analysis. White bars represent cells in the G0/G1 phase, black bars represent cells in the S phase, and pixelated bars represent cells in the G2/M
phase. Means and standard error of the means (SEMs) of 3 independent biological experiments (n = 3) are presented. Two-way ANOVA
followed by Tukey multiple comparison test was performed to analyse diﬀerences between the cell cycle distributions of control treatment
and AmB, L-NAME, or AmB+L-NAME treatment and between cell cycle distributions of AmB treatment and AmB+L-NAME
treatment. ∗ , ∗∗ , ∗∗∗ , and ∗∗∗∗ represent P < 0 05, P < 0 01, P < 0 001, and P < 0 0001, respectively. Multiplicity-adjusted P values
are presented in the main text.
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Upon treatment of S. cerevisiae with AmB in the presence
of L-NAME, not only an increased level of superoxide radi-
cals was found as compared to treatment with AmB alone,
but also an accelerating eﬀect on these levels was observed
(Figures 3(a) and 3(b)). Our DMF approach, allowing a
detailed kinetic study at a single-cell level, showed that super-
oxide radicals accumulated in a biphasic manner during
AmB treatment in the presence of L-NAME, resulting in
two superoxide radical accumulation peaks at 75min and
150min, respectively. This was not observed for cells
treated with AmB in the absence of L-NAME, where a super-
oxide radical accumulation peak seemed to manifest at
180min, the endpoint of this study (Figures 3(c) and 3(d)).
Interestingly, all cell responses, being superoxide radical
accumulation, membrane permeabilization, and loss of pro-
liferative capacity, presented themselves signiﬁcantly faster,
as compared to these responses during treatment with AmB
alone. Therefore, it might well be that L-NAME solely accel-
erated AmB action with respect to superoxide radical accu-
mulation and membrane permeabilization, and hence,
similar outcomes might be expected for treatment with
AmB alone over a longer period of time (i.e., >180min).
Whether, this is the case that requires further investigation.
This hypothesis is supported by the fact that L-NAME acts
fungistatic (MIC against S. cerevisiae of 250mM), however
not fungicidal when administered alone (Supplemental
Information S6 Figure), and does not aﬀect the level of super-
oxide radicals, membrane permeabilization, and proliferative
capacity of control cells (Figure 2), suggesting that the
observed eﬀect on cell responses is not caused by a similar
and dual action of L-NAME and AmB, as is often the case
for synergistic interactions.
Secondly, and most notably, L-NAME had a strong
enhancing eﬀect on AmB-induced loss of proliferative
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Figure 7: AmB induced accumulation of superoxide and nitric oxide radicals in C. albicans and decreased the number of cells that are able to
proliferate. Exponential C. albicans cultures were treated with diﬀerent concentrations of AmB for 3 h at room temperature and subjected to
ﬂow cytometry or plating assays. (a) Levels of superoxide radical detected by dihydroethidium (DHE) ﬂuorescence and ﬂow cytometry. (b)
Levels of nitric oxide radical detected by 4-amino-5-methylamino-2′,7′-diﬂuoroﬂuorescein diacetate (DAF-FM DA) ﬂuorescence and ﬂow
cytometry. (c) Number of CFU/mL in Log-scale, assessed by plating assays and CFU counting. Means and standard errors of the means
(SEMs) of at least 3 independent biological experiments (n ≥ 3) are presented. Two-way ANOVA followed by Dunnett multiple
comparison test was performed to analyse statistically signiﬁcant diﬀerences in the number of DHE- and DAF-FM DA-positive cells and
cells able to proliferate between control treatment and treatment with diﬀerent concentrations of AmB. ∗ and ∗∗∗∗ represent P < 0 05
and P < 0 0001, respectively.
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capacity in yeast: within 15min, approximately 99.5% of the
cells lost their proliferative capacity when subjected to AmB
treatment in the presence of L-NAME. In contrast, treatment
with AmB alone did not reach a similar negative impact on
proliferative capacity of cells within 180min (Figure 4(c)).
This suggest also that here nitric oxide radicals play an
important, beneﬁcial, role in the response towards AmB.
Yet, we showed that nitric oxide radicals only accumulated
from 30min onwards (Supplemental Information S2 Figure).
Hence, L-NAME seemed to have an additional eﬀect apart
from inhibiting nitric oxide radical production, resulting in
enhancement of AmB fungicidal activity, and this eﬀect
occurred within 15min of treatment (event Y in Figure 9).
Interestingly, cells receiving treatment with AmB and L-
NAME were able to accumulate superoxide radicals only
after 30min, suggesting that these accumulated positive cells
were still metabolically active and that AmB-L-NAME-
treated cells might use increased levels of superoxide radicals,
and thus oxidative stress, to enter a programmed cell death
pathway. In addition, as the rapid loss of proliferative
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Figure 8: L-NAME signiﬁcantly decreased the number of AmB-treated cells that are able to proliferate in C. albicans (a) and C. glabrata (b).
Exponential C. albicans and C. glabrata cultures were treated with diﬀerent dosages of AmB in the presence (white bars) or absence (black
bars) of 200mM L-NAME for 180min at 37°C and subjected to plating assays. Means and standard errors of the means (SEMs) of 3
independent biological experiments (n = 3) are presented. Two-way ANOVA followed by Tukey multiple comparison test was performed
to analyse signiﬁcant diﬀerences between the two treatments; ∗ , ∗∗ , and ∗∗∗ represent P < 0 05, P < 0 01, and P < 0 001, respectively.
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Figure 9: Schematic overview of the major ﬁndings on AmB mechanism of action in this study. Within 15min, AmB caused cell cycle arrest
in the G2/M phase and induced a yet to be elucidated event X, the latter leading to loss of proliferative capacity in yeast. These eﬀects were
independent of nitric oxide radicals, superoxide anion radicals, and membrane permeabilization. After 30min, AmB induced the
accumulation of superoxide radicals, which was associated with membrane permeabilization and loss of proliferative capacity in yeast, and
was partially blocked by beneﬁcial action of nitric oxide radicals. Interestingly, the combinatorial action of AmB and L-NAME induced a
yet to be identiﬁed event Y within 15min, which was independent of nitric oxide radicals, and enhanced the eﬀect of event X, leading to
enhanced loss of proliferative capacity in yeast.
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capacity of cells upon combined treatment with AmB and
L-NAME could not be explained by superoxide radical
accumulation and membrane permeabilization, it seems
that mechanisms other than these underlie the negative
eﬀect on the proliferative capacity of cells during the ﬁrst
15min of AmB treatment in the presence of L-NAME
(i.e., event X in Figure 9). A plausible explanation for the loss
of proliferative capacity, independent of oxidative stress and
nonapoptotic cell death, is cell cycle arrest. We showed that
AmB induced cell cycle arrest in the G2/M phase in yeast
within 15min of treatment. These data are in line with
other reports on the eﬀect of AmB on the cell cycle in
mammalian cell lines [52, 53]. However, this eﬀect was
found to be independent of L-NAME, indicating that cell
cycle arrest could not account for the observed increased
loss of proliferative capacity when cells were treated with
the AmB-L-NAME combination.
Overall, it seems that nitric oxide radicals play a beneﬁ-
cial role in AmB antifungal activity, as further demonstrated
by the S-nitrosoglutathione-induced inhibition of AmB’s
killing activity (Figure 5). Nitric oxide radicals were previ-
ously shown to protect bacteria against a wide spectrum of
antibiotics by alleviating the oxidative stress imposed by
them [54]. In addition, nitric oxide radicals were reported
to aﬀect fungal cell death, both in beneﬁcial and destructive
manners. Speciﬁcally, increased intracellular nitric oxide rad-
ical levels are suggested to play a cytoprotective role in yeast
during stress from heat-shock and hydrostatic pressure [55].
In contrast, PAF26-induced production of nitric oxide radi-
cals was correlated to its antifungal activity, and administer-
ing L-NAME partially restored yeast growth in the presence
of PAF26, indicating that nitric oxide radicals play an impor-
tant role in PAF26-induced cell death [44]. In line, Almeida
and colleagues showed that nitric oxide is a crucial mediator
of H2O2-induced apoptosis in yeast and that blockage of
nitric oxide radical production by L-NAME decreased the
intracellular levels of ROS, thereby increasing survival [46].
Interestingly, in our study, L-NAME increased the accumula-
tion of superoxide radicals during AmB treatment, while
decreasing the proliferative capacity of cells in the presence
of AmB, and thus decreasing survival. It seems that a nitric
oxide radical-dependent tolerance system is switched on
upon AmB treatment in yeast, perhaps similar to the system
recently described by Nasuno and colleagues [56]. In that
study, a downstream pathway of nitric oxide radicals
involved in high-temperature stress tolerance in yeast was
unravelled. They showed that nitric oxide radicals activated
the transcription factor Mac1 that on its turn induced the
CTR1 gene and resulted in increased cellular copper levels,
which then resulted in activation of Sod1, a superoxide
dismutase [56]. Alternatively, it could also be that nitric oxide
activates, potentially via S-nitrosylation, AmB tolerance
pathways such as the yeast HOG pathway [57, 58]. How
exactly tolerance to AmB via nitric oxide production is
mediated requires further investigation.
We further translated the most prominent ﬁndings to the
human pathogens, Candida albicans and Candida glabrata,
and found that treatment of C. albicans or C. glabrata with
AmB in the presence of L-NAME signiﬁcantly increases the
loss of proliferative capacity, as compared to treatment with
AmB alone, suggesting that treatment of AmB in the pres-
ence of L-NAME might have a clinical relevance. L-NAME
has been extensively studied in in vitro, ex vivo, and in vivo
systems (reviewed in [59]). It was shown to inhibit corneal
angiogenesis under chemical growth factor stimulation in
rabbits [60] and improve leucocyte adherence and emigra-
tion to venular endothelium, characteristic of acute inﬂam-
mation, in cat jejuni [61]. In addition, L-NAME was found
to modulate hemodynamics in dogs [62], ewes [63], and
guinea pigs [64] and was shown to reverse sepsis-associated
hypotension in various animal models [65]. In humans, L-
NAME was tested to treat hypotension, asthma, and sepsis.
In view of the latter, L-NAME increased the systemic vascu-
lar resistance and blood pressure in septic patients [66, 67].
In treatment of asthma, no adverse eﬀects were found in
healthy volunteers and patients with asthma, and results on
exhaled nitric oxide levels indicated that L-NAME might be
used for treatment of asthma [68]. Finally, L-NAME
increased the mean arterial pressure and cerebral blood ﬂow,
treating hypotension in patients with tetraplegia. No adverse
eﬀects on healthy volunteers or patients were found [69–71].
Hence, although L-NAME as such is not used in a clinical
setting to date, it has been studied extensively in humans dur-
ing the past decades.
AmB, on the other hand, is used in clinical settings to
treat invasive fungal infections. However, its applicability is
limited due to its nephrotoxicity and hence, it must be used
with care [26]. Recent ﬁndings indicated that AmB exerts
its antifungal action by extracting ergosterol from the plasma
membrane, resulting in loss of cell membrane integrity, inter-
ference with ergosterol-depending cellular processes, and
ultimately cell death [29]. In addition, AmB treatment causes
a signiﬁcant loss of fungal replication competency and
numerous morphological and physiological eﬀects on sus-
ceptible yeast cells, including cytoplasm shrinking, abnormal
nuclear and mitochondrial morphologies, and oxidative
stress [72]. Finally, Teixeira-Santos and colleagues showed
that pathogenic and nonpathogenic yeast cells develop com-
pensatory responses towards AmB treatment, related to
membrane polarization, metabolic activity, and ROS produc-
tion, depending on the drug concentration and the duration
of the treatment [14]. Likewise, we found that treatment of
yeast cells with clinically relevant AmB concentrations (i.e.,
0.1μM to 21.6μM AmB [14, 73]) induces the accumulation
of superoxide radicals, in addition to nitric oxide radicals,
in S. cerevisiae and C. albicans. Furthermore, we found that
clinically relevant AmB concentrations signiﬁcantly increase
the loss of proliferative capacity of S. cerevisiae, C. albicans,
and C. glabrata in the presence of L-NAME.
5. Conclusions
In conclusion, we showed that L-NAME can increase and
accelerate AmB-induced superoxide radical accumulation
and loss of proliferative capacity in S. cerevisiae, the latter
was conﬁrmed in the human pathogens C. albicans and C.
glabrata. Moreover, we found that the production of nitric
oxide radicals seems to constitute a tolerance mechanism
14 Oxidative Medicine and Cellular Longevity
that is induced by AmB treatment and partially counteracts
AmB activity. Moreover, the combinatorial action of AmB
and L-NAME induced an additional, yet to be elucidated,
event that further enhanced AmB’s fungicidal activity. The
eﬀects of both AmB and L-NAME have been extensively
studied in various in vitro and in vivo models, pointing
towards the potential of AmB-L-NAME combination treat-
ment. However, further research on pharmacology and
toxicology of the AmB-L-NAME combination needs to be
performed in order to assess its potential clinical relevance.
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